Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

Roivant Sciences Ltd. (ROIV)

11.56
-0.02
(-0.13%)
As of 1:31:55 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ROIV

Recent News: ROIV

View More
Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug

Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug
Investor's Business Daily 10 days ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
GlobeNewswire 11 days ago
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.

Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose.
Investor's Business Daily last month
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
GlobeNewswire last month
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
GlobeNewswire last month
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
GlobeNewswire last month

Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board
GlobeNewswire 2 months ago
Roivant Sciences price target lowered to $12 from $13 at BofA

Roivant Sciences price target lowered to $12 from $13 at BofA
TipRanks 2 months ago
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts

News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts
Simply Wall St. 2 months ago
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
GlobeNewswire 2 months ago
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care
GlobeNewswire 2 months ago
View More

Related Tickers

IMVT Immunovant, Inc.
16.08
+1.13%
 
ABUS Arbutus Biopharma Corporation
3.6400
+0.83%
 
CYTK Cytokinetics, Incorporated
36.83
-14.19%
 
BBIO BridgeBio Pharma, Inc.
38.80
+1.03%
 
PCVX Vaxcyte, Inc.
36.11
+2.47%
 
LEGN Legend Biotech Corporation
33.22
-2.18%
 
GMAB Genmab A/S
21.38
+2.15%
 
INSM Insmed Incorporated
72.70
+0.08%
 
NUVL Nuvalent, Inc.
77.74
+1.97%
 
ARGX argenx SE
650.30
+1.63%
 
Waiting for permission
Allow microphone access to enable voice search

Try again.